Home  |  Sitemap
You need to upgrade your Flash Player.
Photo Flash Gallery requires Macromedia Flash, version 8 or greater. Please click here to download.
Or, if you're absolutely positive you have Flash 8 or greater, click here to force the site to load.
 
     
   
APPLICATIONS › PHARMA

Medical and Pharmaceutical Applications

Functional Genomic Fingerprinting (FGF) technology provides a powerful way to discover the defective genes in disorders involving multiple genes, such as type II diabetes, hypertension, Alzheimer’s disease, asthma, allergies and various types of cancer.

Because the technology platform is disease-independent, it can be used to reveal disease-causing genes in any disease with a genetic basis, inherited or acquired.

FGF is far more effective at finding mutated genes than other currently available techniques, such as microarray, HapMap, AFLP, RAPD, or positional cloning.

Using FGF to find disease-related genes will save significant effort, money and time.

Discover pharmaceutical drugs rapidly by finding the right disease-causing genes
Discovery of disease-causing genes will make it possible to assess risk for genetic diseases, to diagnose genetic diseases earlier, and to develop targeted pharmaceutical drugs more efficiently. Despite enormous efforts, finding the right disease-causing gene(s) has been a gargantuan task, especially for multi-genic disorders which cause major illnesses such as type II diabetes, hypertension and asthma. Genome Technologies LLC’s breakthrough FGF technology makes this process simpler and cost-effective

Revive major drugs by identifying genetic markers responsible for adverse effects
A number of drugs, which entailed a great investment of time and money to develop, have been removed from the market since it was discovered that some individuals have unusual adverse side effects. Adverse drug effects in individuals may be due to variations or mutations in specific genes that affect the metabolism of a particular pharmaceutical drug. FGF technology can quickly identify the genetic markers responsible for these adverse effects. Once the individuals that have the particular genetic variant(s) that affects their metabolism of the drug have been identified, then these useful drugs that were withdrawn due to adverse effects on just a few patients can be returned to the market.

Personalization of medicine
FGF technology effectively identifies the genes that are responsible for adverse drug effects in a particular patient. Once the genetic culprits are identified, genetic markers can be used clinically to aid health care providers in prescribing the right drug to avoid adverse side effects.

   
     
 
  © 2007-08 Genome Technologies Llc.,